Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 22Plasma cell 2Other solid neoplasm 2Lymphoid 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × 1-dodecylpyridoxal × Lymphoid × Clear all
NCT06425302 2026-01-08

GOLSEEK-2

Celgene

Phase 2 Active not recruiting
90 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡